Cited by 99Liver Diseases and ImmunityCholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Incidence of cancer in primary biliary cirrhosis: the Mayo experience

Open access
Nijhawan, Pardeep K., Therneau, Terry M., Dickson, Rolland E., Boynton, Jessica, Lindor, Keith D.·1999·Hepatology

Abstract

Patients with primary biliary cirrhosis (PBC) may be at increased risk for malignancies. Several studies have addressed the risk of specific malignancies; however, there is little information about overall incidences of malignancies in these patients. We hypothesize that these patients may be at an increased risk for cancer. We performed a retrospective chart review evaluating patients with the diagnosis of PBC and malignancies. We reviewed records of patients with PBC presenting to the Mayo Clinic between 1976 and 1985. The diagnosis of PBC was made using evidence of cholestasis, positive antimitochondrial antibody titers and liver biopsy findings consistent with PBC. The incidence of malignancies were then compared with published data by the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute. Of the 1,692 patients with PBC in the Mayo Clinic data base, 114 patients were identified with primary cancer. The number of malignancies was higher than would be anticipated by chance alone; with 93 observed versus 62.4 expected events (P < .001). Hepatobiliary malignancies had a relative risk of 46 (P < .0001) for women and 55 (P < .0001) in men. There was a dramatic increased risk for development of hepatobiliary malignancies. PBC patients might benefit from more aggressive surveillance for hepatobiliary malignancies during their lifetime

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510290511

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Regular imaging surveillance is linked to improved clinical outcomes in PBC patients who develop HCC.

    “Surveillance with regular imaging was associated with better clinical outcome of PBC patients who develop HCC.(227)(228)(229)(230)”

    From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [228]

    The Discussion recommends that PBC patients might benefit from more aggressive surveillance for hepatobiliary malignancies. It does not specify regular imaging or report that surveillance was associated with better outcomes among patients who developed HCC. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 20 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Ries LAG, Miller BA, Hankey BF, Chu KC, Tarone RE, Kessler LG, Edwards BK. SEER Cancer Statistics Review: 1973-1991. Bethesda, MD: National Cancer Institute. NIH pub No. 94-2789, 1994.

Cited by

Sorted by citations

Authors
Nijhawan, P. K., Therneau, T. M., Dickson, R. E., Boynton, J., & Lindor, K. D.
Affiliations
Mayo Clinic (US)
Corresponding author
Lindor, Keith D.
Venue
Hepatology
Published
1999-05
Volume
29
Issue
5
Pages
1396-1398
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2021512776
Cited by
99
References
20
Citations by year
2024: 2 · 2023: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 5
FWCI
2.64
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, cancer incidence, hepatobiliary malignancies, cancer risk, cholestatic liver disease, antimitochondrial antibodies, cancer surveillance, sex differences in cancer risk
MeSH terms
Adolescent, Adult, Aged, Bile Duct Neoplasms, Child, Child, Preschool, Female, Humans, Infant, Liver Cirrhosis, Biliary, Liver Neoplasms, Male, Medical Records, Neoplasms, Retrospective Studies, Risk Factors, Incidence, Sex Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review